Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Needlescopic surgery for broad ligament hernia: A case report.

Koizumi N, Ariyoshi Y, Fujiki H, Sakakura C.

Asian J Endosc Surg. 2019 Feb 14. doi: 10.1111/ases.12692. [Epub ahead of print]

PMID:
30767408
2.

[A Case of Esophageal Gastrointestinal Stromal Tumor Resected by Mediastinoscope-Assisted Transhiatal Esophagectomy].

Ariyoshi Y, Koizumi N, Yasuoka R, Nakamura K, Fujiki H, Shiozaki A, Fujiwara H, Sakakura C.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2267-2269. Japanese.

PMID:
30692353
3.

The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.

Fujiki H, Sueoka E, Watanabe T, Suganuma M.

J Cancer Res Clin Oncol. 2018 Dec;144(12):2339-2349. doi: 10.1007/s00432-018-2765-7. Epub 2018 Oct 20. Review.

4.

Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.

Rawangkan A, Wongsirisin P, Namiki K, Iida K, Kobayashi Y, Shimizu Y, Fujiki H, Suganuma M.

Molecules. 2018 Aug 18;23(8). pii: E2071. doi: 10.3390/molecules23082071.

5.

Enzymatic and molecular characterization of α-1,3-glucanase (AglST2) from Streptomyces thermodiastaticus HF3-3 and its relation with α-1,3-glucanase HF65 (AglST1).

Cherdvorapong V, Fujiki H, Suyotha W, Takeda Y, Yano S, Takagi K, Wakayama M.

J Gen Appl Microbiol. 2019 Mar 8;65(1):18-25. doi: 10.2323/jgam.2018.04.001. Epub 2018 Jul 17.

6.

Enzymatic and molecular characterization of an acidic and thermostable chitinase 1 from Streptomyces thermodiastaticus HF 3-3.

Take K, Fujiki H, Suyotha W, Hayashi J, Takagi K, Yano S, Wakayama M.

J Gen Appl Microbiol. 2018 Sep 27;64(4):190-197. doi: 10.2323/jgam.2017.12.002. Epub 2018 Apr 27.

7.

Aqueous Phase Synthesis of CuIn Alloy Nanoparticles and Their Application for a CIS (CuInSe₂)-Based Printable Solar Battery.

Takahashi H, Fujiki H, Yokoyama S, Kai T, Tohji K.

Nanomaterials (Basel). 2018 Apr 6;8(4). pii: E221. doi: 10.3390/nano8040221.

8.

Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells.

Fujiki H, Watanabe T, Sueoka E, Rawangkan A, Suganuma M.

Mol Cells. 2018 Feb 28;41(2):73-82. doi: 10.14348/molcells.2018.2227. Epub 2018 Jan 31. Review.

9.

A novel thermostable α-1,3-glucanase from Streptomyces thermodiastaticus HF 3-3.

Suyotha W, Fujiki H, Cherdvorapong V, Takagi K, Yano S, Wakayama M.

J Gen Appl Microbiol. 2017 Nov 17;63(5):296-304. doi: 10.2323/jgam.2017.02.001. Epub 2017 Sep 26.

10.

Human cancer stem cells are a target for cancer prevention using (-)-epigallocatechin gallate.

Fujiki H, Sueoka E, Rawangkan A, Suganuma M.

J Cancer Res Clin Oncol. 2017 Dec;143(12):2401-2412. doi: 10.1007/s00432-017-2515-2. Epub 2017 Sep 23. Review.

11.

Phorbol esters in seed oil of Jatropha curcas L. (saboodam in Thai) and their association with cancer prevention: from the initial investigation to the present topics.

Fujiki H, Suttajit M, Rawangkan A, Iida K, Limtrakul P, Umsumarng S, Suganuma M.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1359-1369. doi: 10.1007/s00432-017-2341-6. Epub 2017 Jan 25. Review.

12.

Down-regulation of histone deacetylase 4, -5 and -6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin.

Oya Y, Mondal A, Rawangkan A, Umsumarng S, Iida K, Watanabe T, Kanno M, Suzuki K, Li Z, Kagechika H, Shudo K, Fujiki H, Suganuma M.

J Nutr Biochem. 2017 Apr;42:7-16. doi: 10.1016/j.jnutbio.2016.12.015. Epub 2017 Jan 8.

PMID:
28103535
13.

Biophysical Approach to Mechanisms of Cancer Prevention and Treatment with Green Tea Catechins.

Suganuma M, Takahashi A, Watanabe T, Iida K, Matsuzaki T, Yoshikawa HY, Fujiki H.

Molecules. 2016 Nov 18;21(11). pii: E1566. Review.

14.

Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure.

Ikeda T, Iwanaga Y, Watanabe H, Morooka H, Akahoshi Y, Fujiki H, Miyazaki S.

J Cardiovasc Pharmacol. 2015 Nov;66(5):487-96. doi: 10.1097/FJC.0000000000000300.

PMID:
26248278
15.

Primary cancer prevention by green tea, and tertiary cancer prevention by the combination of green tea catechins and anticancer compounds.

Fujiki H, Sueoka E, Watanabe T, Suganuma M.

J Cancer Prev. 2015 Mar;20(1):1-4. doi: 10.15430/JCP.2015.20.1.1. Review.

16.

Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds.

Fujiki H, Sueoka E, Watanabe T, Suganuma M.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1511-22. doi: 10.1007/s00432-014-1899-5. Epub 2014 Dec 28. Review.

PMID:
25544670
17.

Exploring urinary biomarkers in autosomal dominant polycystic kidney disease.

Kawano H, Muto S, Ohmoto Y, Iwata F, Fujiki H, Mori T, Yan L, Horie S.

Clin Exp Nephrol. 2015 Oct;19(5):968-73. doi: 10.1007/s10157-014-1078-7. Epub 2014 Dec 28.

PMID:
25543187
18.

Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.

Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y.

J Pharmacol Exp Ther. 2014 May;349(2):258-67. doi: 10.1124/jpet.114.213256. Epub 2014 Feb 25.

PMID:
24570071
19.

Cell-surface nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands.

Fujiki H, Watanabe T, Suganuma M.

J Cancer Res Clin Oncol. 2014 May;140(5):689-99. doi: 10.1007/s00432-014-1587-5. Epub 2014 Jan 28.

20.

Gist of Dr. Katsusaburo Yamagiwa's papers entitled "Experimental study on the pathogenesis of epithelial tumors" (I to VI reports).

Fujiki H.

Cancer Sci. 2014 Feb;105(2):143-9. doi: 10.1111/cas.12333. Epub 2014 Jan 17. Review.

21.

Mechanism-based inhibition of cancer metastasis with (-)-epigallocatechin gallate.

Takahashi A, Watanabe T, Mondal A, Suzuki K, Kurusu-Kanno M, Li Z, Yamazaki T, Fujiki H, Suganuma M.

Biochem Biophys Res Commun. 2014 Jan 3;443(1):1-6. doi: 10.1016/j.bbrc.2013.10.094. Epub 2013 Nov 21.

PMID:
24269590
22.

Epithelial-mesenchymal transition in human gastric cancer cell lines induced by TNF-α-inducing protein of Helicobacter pylori.

Watanabe T, Takahashi A, Suzuki K, Kurusu-Kanno M, Yamaguchi K, Fujiki H, Suganuma M.

Int J Cancer. 2014 May 15;134(10):2373-82. doi: 10.1002/ijc.28582. Epub 2013 Nov 19.

23.

Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.

Yamazaki T, Nakamura Y, Shiota M, Osada-Oka M, Fujiki H, Hanatani A, Shimada K, Miura K, Yoshiyama M, Iwao H, Izumi Y.

J Pharmacol Sci. 2013 Sep 20;123(1):58-66. Epub 2013 Sep 3.

24.

Tumor promoters: from chemicals to inflammatory proteins.

Fujiki H, Sueoka E, Suganuma M.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1603-14. doi: 10.1007/s00432-013-1455-8. Epub 2013 Jun 12. Review.

PMID:
23756937
25.

The eleventh Korea-Japan-Germany joint symposium on cancer and ageing research.

Kim EG, Seimiya H, Chung J, Hoheisel J, Lim IK, Fujiki H, Park SC.

J Cancer Res Clin Oncol. 2013 Jun;139(6):901-4. doi: 10.1007/s00432-013-1397-1. Epub 2013 Feb 28. No abstract available.

PMID:
23455879
26.

Tolvaptan, an orally active non-peptide arginine vasopressin V2 receptor antagonist, reduces ascites in rats with chronic liver injury.

Miyazaki T, Fujiki H, Yamamura Y.

Hepatol Res. 2013 Nov;43(11):1224-30. doi: 10.1111/hepr.12073. Epub 2013 Feb 17.

PMID:
23413814
27.

Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.

Yamazaki T, Izumi Y, Nakamura Y, Yamashita N, Fujiki H, Osada-Oka M, Shiota M, Hanatani A, Shimada K, Iwao H, Yoshiyama M.

Circ Heart Fail. 2012 Nov;5(6):794-802. doi: 10.1161/CIRCHEARTFAILURE.112.968750. Epub 2012 Sep 14.

PMID:
22984091
28.

Challenging the effectiveness of green tea in primary and tertiary cancer prevention.

Fujiki H, Imai K, Nakachi K, Shimizu M, Moriwaki H, Suganuma M.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1259-70. doi: 10.1007/s00432-012-1250-y. Epub 2012 Jun 15. Review.

PMID:
22699930
29.

Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.

Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, Fujiki H, Miyazaki S.

Circ Heart Fail. 2012 Jul 1;5(4):484-92. doi: 10.1161/CIRCHEARTFAILURE.111.965392. Epub 2012 May 24.

PMID:
22628529
30.

Green tea: an effective synergist with anticancer drugs for tertiary cancer prevention.

Fujiki H, Suganuma M.

Cancer Lett. 2012 Nov 28;324(2):119-25. doi: 10.1016/j.canlet.2012.05.012. Epub 2012 May 21. Review.

PMID:
22626556
31.

Human gastric cancer development with TNF-α-inducing protein secreted from Helicobacter pylori.

Suganuma M, Watanabe T, Yamaguchi K, Takahashi A, Fujiki H.

Cancer Lett. 2012 Sep 28;322(2):133-8. doi: 10.1016/j.canlet.2012.03.027. Epub 2012 Mar 27. Review.

PMID:
22459353
32.

Higher cell stiffness indicating lower metastatic potential in B16 melanoma cell variants and in (-)-epigallocatechin gallate-treated cells.

Watanabe T, Kuramochi H, Takahashi A, Imai K, Katsuta N, Nakayama T, Fujiki H, Suganuma M.

J Cancer Res Clin Oncol. 2012 May;138(5):859-66. doi: 10.1007/s00432-012-1159-5.

PMID:
22297840
33.

Anti-edematous effects of tolvaptan in experimental rodent models.

Miyazaki T, Sakamoto Y, Yamashita T, Ohmoto K, Fujiki H.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S77-82. doi: 10.1007/s10557-011-6355-z.

PMID:
22120096
34.

Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.

Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S67-76. doi: 10.1007/s10557-011-6350-4.

PMID:
22120095
35.

Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.

Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP.

Am J Physiol Renal Physiol. 2011 Nov;301(5):F1005-13. doi: 10.1152/ajprenal.00243.2011. Epub 2011 Aug 3.

36.

Tumor promoters--microcystin-LR, nodularin and TNF-α and human cancer development.

Fujiki H, Suganuma M.

Anticancer Agents Med Chem. 2011 Jan;11(1):4-18. Review.

PMID:
21269254
37.

Enhanced glucose tolerance in the Brattleboro rat.

Nakamura K, Yamashita T, Fujiki H, Aoyagi T, Yamauchi J, Mori T, Tanoue A.

Biochem Biophys Res Commun. 2011 Feb 4;405(1):64-7. doi: 10.1016/j.bbrc.2010.12.126. Epub 2011 Jan 5.

PMID:
21215256
38.

New cancer treatment strategy using combination of green tea catechins and anticancer drugs.

Suganuma M, Saha A, Fujiki H.

Cancer Sci. 2011 Feb;102(2):317-23. doi: 10.1111/j.1349-7006.2010.01805.x. Epub 2010 Dec 30. Review.

39.

Impaired fracture healing in macrophage migration inhibitory factor-deficient mice.

Kobayashi T, Onodera S, Kondo E, Tohyama H, Fujiki H, Yokoyama A, Yasuda K.

Osteoporos Int. 2011 Jun;22(6):1955-65. doi: 10.1007/s00198-010-1385-0. Epub 2010 Sep 14.

PMID:
20838768
40.
41.

New role of (-)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin.

Saha A, Kuzuhara T, Echigo N, Suganuma M, Fujiki H.

Cancer Prev Res (Phila). 2010 Aug;3(8):953-62. doi: 10.1158/1940-6207.CAPR-09-0247. Epub 2010 Jul 6.

42.

Nucleolin on the cell surface as a new molecular target for gastric cancer treatment.

Watanabe T, Hirano K, Takahashi A, Yamaguchi K, Beppu M, Fujiki H, Suganuma M.

Biol Pharm Bull. 2010;33(5):796-803.

43.

Chronic hyponatremia impairs memory in rats: effects of vasopressin antagonist tolvaptan.

Miyazaki T, Ohmoto K, Hirose T, Fujiki H.

J Endocrinol. 2010 Jul;206(1):105-11. doi: 10.1677/JOE-10-0050. Epub 2010 Apr 14.

PMID:
20392812
44.

Nucleolin as cell surface receptor for tumor necrosis factor-alpha inducing protein: a carcinogenic factor of Helicobacter pylori.

Watanabe T, Tsuge H, Imagawa T, Kise D, Hirano K, Beppu M, Takahashi A, Yamaguchi K, Fujiki H, Suganuma M.

J Cancer Res Clin Oncol. 2010 Jun;136(6):911-21. doi: 10.1007/s00432-009-0733-y. Epub 2010 Jan 5.

PMID:
20049476
45.

Artificial cartilage made from a novel double-network hydrogel: In vivo effects on the normal cartilage and ex vivo evaluation of the friction property.

Arakaki K, Kitamura N, Fujiki H, Kurokawa T, Iwamoto M, Ueno M, Kanaya F, Osada Y, Gong JP, Yasuda K.

J Biomed Mater Res A. 2010 Jun 1;93(3):1160-8. doi: 10.1002/jbm.a.32613.

PMID:
19768793
46.

Structural basis for the Helicobacter pylori-carcinogenic TNF-alpha-inducing protein.

Tsuge H, Tsurumura T, Utsunomiya H, Kise D, Kuzuhara T, Watanabe T, Fujiki H, Suganuma M.

Biochem Biophys Res Commun. 2009 Oct 16;388(2):193-8. doi: 10.1016/j.bbrc.2009.07.121. Epub 2009 Jul 28.

PMID:
19643085
47.

Carcinogenic aspects of protein phosphatase 1 and 2A inhibitors.

Fujiki H, Suganuma M.

Prog Mol Subcell Biol. 2009;46:221-54. doi: 10.1007/978-3-540-87895-7_8. Review.

PMID:
19184590
48.

Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study.

Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki H.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3020-5. doi: 10.1158/1055-9965.EPI-08-0528.

49.

Generation of mouse monoclonal antibody against (-)-epigallocatechin gallate.

Kuzuhara T, Kise D, Shirakawa Y, Sasada K, Suganuma M, Fujiki H.

Biol Pharm Bull. 2008 May;31(5):816-9.

50.

TNF-alpha-inducing protein, a carcinogenic factor secreted from H. pylori, enters gastric cancer cells.

Suganuma M, Yamaguchi K, Ono Y, Matsumoto H, Hayashi T, Ogawa T, Imai K, Kuzuhara T, Nishizono A, Fujiki H.

Int J Cancer. 2008 Jul 1;123(1):117-22. doi: 10.1002/ijc.23484.

Supplemental Content

Loading ...
Support Center